Compare · CMPS vs CMPX
CMPS vs CMPX
Side-by-side comparison of COMPASS Pathways Plc (CMPS) and Compass Therapeutics Inc. (CMPX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CMPS focuses on Biotechnology: Pharmaceutical Preparations, while CMPX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- CMPS is the larger of the two at $1.61B, about 10.0x CMPX ($161.5M).
- CMPS has been more active in the news (3 items in the past 4 weeks vs 2 for CMPX).
- CMPX has more recent analyst coverage (25 ratings vs 17 for CMPS).
- Company
- COMPASS Pathways Plc
- Compass Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.61B
- $161.5M
- 1M return
- -28.35%
- -
- 1Y return
- +59.11%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 3
- 2
- Recent ratings
- 17
- 25
COMPASS Pathways Plc
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest CMPS
- Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Compass Pathways Appoints Kelley Boucher as Chief People Officer
- Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
- Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
- Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
- Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
- Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
- Compass Pathways to Participate in Investor Conferences the Week of September 14th
- Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
Latest CMPX
- Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Accounting Officer Lerner Neil bought $18,400 worth of shares (20,000 units at $0.92), increasing direct ownership by 5% to 420,000 units (SEC Form 4)
- Chief Accounting Officer Lerner Neil bought $2,850 worth of shares (2,500 units at $1.14), increasing direct ownership by 0.63% to 400,000 units (SEC Form 4)
- Compass Therapeutics downgraded by Wedbush with a new price target
- Compass Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
- SEC Form SCHEDULE 13G filed by Compass Therapeutics Inc.
- SEC Form 10-Q filed by Compass Therapeutics Inc.
- Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update